ï »¿

xml: lang = “en” lang = “en” xmlns = “http://www.w3.org/1999/xhtml”>

Arbovax passport is an important milestone in the development of vaccine against dengue fever

Raleigh, NC (Business Wire) 14 October 2010

Arbovax, a company at an early stage of development of vaccines against diseases transmitted by insects to protect, has taken an important step in the development of a vaccine against dengue fever news with the successful completion of the non- human primate studies. The original study, which focused on dengue serotype 2 has already shown promising results and has the potential to provide protection at a dose? Unlike other technologies developed, the treatment with multiple doses. The test was carried out using the RxGen and Walter Reed Army Institute of

research.

Arbovaxâ? s unique strategy is based on the development of vaccines on their own host range mutation replicate the ability of the virus in different hosts based limits. This technology has been able Arbovax stable genetic modification of viruses to replicate efficiently in mammalian cells, the development of a strong immune response without creating the risk of the disease. Another advantage of the Arbovaxâ? The approach is that it produces very profitable.

â? We are very excited about these positive results at the beginning and move forward with the development of a product tetravalent â? States Malcolm Thomas, president and CEO of Arbovax. â? We believe that our new and unique approach represents a breakthrough in the development of vaccines that provide strong protection and durable with a single dose. In addition to protection against potentially fatal dengue fever, our technology was used to treat a variety of insect-borne viral diseases, including West Nile, yellow fever and Japanese> ????

of dengue

Dengue fever is a potentially fatal mosquito-borne virus. There was a significant increase in cases over the past sixty years on the basis of global climate change and rapid urbanization, the production of a dengue fever outbreak of major infectious diseases

Dengue haemorrhagic fever (DHF), a potentially lethal complication, was recognized 1950th
More than 2.5 billion people, two fifths of the world’s population, are now in danger.
The disease is now endemic in over 100 countries in Africa, the Americas, Eastern Mediterranean, Southeast Asia and Western Pacific.
In 2007 alone there were 890 000 reported cases of dengue fever in the Americas.
About 500,000 cases of DHF require hospitalization each year.
About 2.5% of those affected die, to be a high proportion of children.
Without proper treatment, DHF mortality exceeding 20%. About

Arbovax

Arbovax is in preclinical development of vaccines to protect against diseases that are committed transmitted by mosquitoes, which infect together more than 100 million people each year. Arbovaxâ? S original goal, dengue fever, second to malaria and tuberculosis by the World Health Organization for its devastating global impact. The company’s articles of association? S research and development led to three U.S. patents, which apply to all insect-borne viruses, including alphaviruses, bunyaviruses and flaviviruses. The company, in Raleigh, NC based, has more than 0,000 funding received from the North Carolina Biotechnology Center, and 0.5 million in Series A Financing

For further information on Arbovax and vaccine technology, please visit www.arbovax.com.

# # #

clear = “all”

class = “small-text”>

Vocus © Copyright 1997-2010, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Virus Protection